Obstetrics, Gynecology and Reproduction

Advanced search


Full Text:


Cerebral venous thrombosis is a rare, life-threatening condition, which has now become more frequently diagnosed by advances in imaging techniques. The most common risk factors for cerebral venous thrombosis include pregnancy, postpartum period, use of oral contraceptives. Proved a leading role in the pathogenesis of thrombophilic states of cerebral thrombosis, especially FV Leiden mutation and prothrombin G20210A. The article highlights the pathogenesis, differential diagnosis and therapy of cerebral venous thrombosis in obstetric practice, as well as problems of pregnancy management in patients with history of cerebral venous thrombosis.

About the Authors

A. D. Makatsariya
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation

S. V. Akinshina
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation

V. O. Bitsadze
State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation


1. Bates S.M., Greer I.A., Pabinger I. et al. American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133 (6): 844-886.

2. Bazzan M., Tamponi G., Schinco P., Vaccarino A., Foli C., Gallone G., Pileri A. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999 Dec; 78 (12): 539-43.

3. Carlin A.J., Farquharson R.G., Quenby S.M., Topping J., Fraser W.D. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004 May; 19 (5): 1211-4.

4. Chan W.S. Venous thromboembolism in pregnancy. Expert Rev Cardiovasc Ther. 2010 Dec; 8 (12): 1731-40.

5. Coomarasamy A., Honest H., Papaioannou S. et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003 Jun; 101 (6): 1319-32.

6. Dentali F., Crowther M., Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a metaanalysis. Blood. 2006 Apr 1; 107 (7): 2766-73.

7. Dentali F., Gianni M., Crowther M.A., Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006 Aug 15; 108 (4): 1129-34.

8. Dentali F., Squizzato A., Gianni M., De Lodovici M.L., Venco A., Paciaroni M., Crowther M., Ageno W. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost. 2010 Nov; 104 (5): 1055-62.

9. Deschiens M.A., Conard J., Horellou MH et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996 Oct; 27 (10): 1724-30.

10. DeVeber G. In pursuit of evidence-based treatments for paediatric stroke: the UK and Chest guidelines. Lancet Neurol. 2005 Jul; 4 (7): 432-6.

11. Empson M., Lassere M., Craig J., Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005 Apr 18; (2): CD002859.

12. Ferro J.M., Canhão P., Stam J., Bousser M.G., Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 Mar; 35 (3): 664-70.

13. Ferro J.M., Crassard I., Coutinho J.M., Canhão P., Barinagarrementeria F., Cucchiara B., Derex L., Lichy C., Masjuan J., Massaro A., Matamala G., Poli S., Saadatnia M., Stolz E., Viana-Baptista M., Stam J., Bousser M.G. Second International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT 2) Investigators. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. 2011 Oct; 42 (10): 2825-31.

14. Greer I.A., Nelson-Piercy C. Low-molecularweight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005 Jul 15; 106 (2): 401-7.

15. Hills F.A., Abrahams V.M., González-Timón B. et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006 Apr; 12 (4): 237-43.

16. James A.H., Bushnell C.D., Jamison M.G. et al. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet. Gynecol. 2005 Sep; 106 (3): 509-16.

17. Khealani B.A., Mapari U.U., Sikandar R. Obstetric cerebral venous thrombosis. J. Pak Med. Assoc. 2006 Nov; 56 (11): 490-3.

18. Kitchens K.S., Alving B.M., Kessler C.M. Consultative haemostasis and thrombosis. Elsivier Science. 2002; P. 617.

19. Marongiu F., Tosetto A., Palareti G. Special indications for vitamin K antagonists: a review. Intern Emerg Med. 2012 Feb; 7 (1): 21-5.

20. Martinelli I., Battaglioli T., Pedotti P., Cattaneo M., Mannucci P.M. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003 Aug 15; 102 (4): 1363-6.

21. Martinelli I., Bucciarelli P., Passamonti S.M., Battaglioli T., Previtali E., Mannucci P.M. Longterm evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010 Jun 29; 121 (25): 2740-6.

22. Martinelli I., Franchini M., Mannucci P.M. How I treat rare venous thromboses. Blood. 2008 Dec 15; 112 (13): 4818-23.

23. Martinelli I., Landi G., Merati G., Cella R., Tosetto A., Mannucci P.M. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb. Haemost. 1996 Mar; 75 (3): 393-4.

24. Martinelli I., Sacchi E., Landi G., Taioli E., Duca F., Mannucci P.M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N. Engl. J. Med. 1998 Jun 18; 338 (25): 1793-7.

25. Martinelli I. Cerebral vein thrombosis. Thromb Res. 2013 Jan; 131 (1): 51-4.

26. Mello G., Parretti E., Fatini C. et al. Lowmolecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005 Jan; 45 (1): 86-91.

27. Passamonti S.M., Biguzzi E., Cazzola M., Franchi F., Gianniello F., Bucciarelli P., Pietra D., Mannucci P.M., Martinelli I. The JAK2 V617F mutation in patients with cerebral venous thrombosis. J. Thromb Haemost. 2012 Jun; 10 (6): 998-1003.

28. Sanson B.J., Lensing A.W., Prins M.H. et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb. Haemost. 1999 May; 81 (5): 668-72.

29. Stam J. Thrombosis of the cerebral veins and sinuses. N. Engl. J. Med. 2005 Apr 28; 352 (17): 1791-8.

30. Warkentin T.E. Heparin-induced thrombocytopenia. Hematol. Oncol. Clin. North. Am. 2007 Aug; 21 (4): 589-607.


For citations:

Makatsariya A.D., Akinshina S.V., Bitsadze V.O. CEREBRAL VENOUS THROMBOSIS IN OBSTETRICS AND GYNECOLOGY. Obstetrics, Gynecology and Reproduction. 2014;8(1):54-59. (In Russ.)

Views: 392

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)